<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776438</url>
  </required_header>
  <id_info>
    <org_study_id>GID25</org_study_id>
    <nct_id>NCT00776438</nct_id>
  </id_info>
  <brief_title>Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines</brief_title>
  <official_title>Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To further characterize the immune responses induced after an influenza vaccination performed
      either via the ID or the IM routes in two clearly distinct populations.

      Objectives:

        -  To describe the immune response per age group and vaccine group after vaccination.

        -  To describe the safety of the vaccines per age group and per vaccine group after
           vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning immune response to an inactivated, split-virion, influenza vaccine.</measure>
    <time_frame>21 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To provide information concerning the safety of inactivated, split-virion, influenza vaccine.</measure>
    <time_frame>21 days post-vaccination and entire study duration</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Influenza</condition>
  <condition>Orthomyxovirus Infections</condition>
  <condition>Myxovirus Infection</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult, age 18 to 40 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult, age 18 to 40 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elderly, age 60 to 85 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elderly, age 60 to 85 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated, split-virion, influenza vaccine</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Study Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated, split-virion, influenza vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 2</arm_group_label>
    <other_name>Vaxigrip®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated, split-virion influenza vaccine</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Study Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated, split-virion influenza vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 4</arm_group_label>
    <other_name>Vaxigrip®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Aged 18 to 40 years (adults) or 60 to 85 years (elderly)

          -  Provision of a signed informed consent

          -  Able to attend all scheduled visits and comply with all trial procedures

          -  For a woman of child-bearing potential, avoid becoming pregnant (use of an effective
             method of contraception or abstinence) for at least 4 weeks prior to vaccination,
             until 4 weeks after vaccination

          -  Entitlement to national social security.

        Exclusion Criteria :

          -  For a woman of child-bearing potential, known pregnancy or positive urine pregnancy
             test

          -  Breast-feeding woman

          -  Participation in another clinical trial investigating a vaccine, drug, medical device
             or a medical procedure in the 4 weeks preceding the trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroids therapy

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or to a vaccine containing any of the
             same substances

          -  Chronic illness, at a stage that could interfere with trial conduct or completion, in
             the opinion of the Investigator

          -  Current alcohol abuse or drug addiction, which may interfere with the subject's
             ability to comply with trial procedures

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with the assessment of immune response

          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination

          -  Planned receipt of any vaccine in the 4 weeks following the trial vaccination

          -  Known Human Immunodeficiency Virus, Hepatitis B or Hepatitis C seropositivity

          -  Previous vaccination against Influenza in the previous 6 months

          -  Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding the
             inclusion contraindicating IM vaccination

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent

          -  Febrile illness (oral temperature &gt;=37.5°C) or moderate or severe acute
             illness/infection on the day of vaccination, according to investigator judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lyon Sud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <results_reference>
    <citation>Nougarede N, Bisceglia H, Rozières A, Goujon C, Boudet F, Laurent P, Vanbervliet B, Rodet K, Hennino A, Nicolas JF. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults. Hum Vaccin Immunother. 2014;10(9):2713-20. doi: 10.4161/hv.29695.</citation>
    <PMID>25483667</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2008</study_first_submitted>
  <study_first_submitted_qc>October 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Orthomyxoviruses</keyword>
  <keyword>Myxovirus Infection</keyword>
  <keyword>Inactivated Split-virion influenza vaccine</keyword>
  <keyword>Adults</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

